Published in Neoplasia on November 01, 2015
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods (2003) 18.51
Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods (2006) 12.63
SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol (2002) 8.89
Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer (2005) 8.70
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol (2007) 8.08
The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell (2002) 7.35
Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem (2001) 5.89
A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 5.12
Bone morphogenetic protein receptors and signal transduction. J Biochem (2009) 4.51
Smad6 inhibits signalling by the TGF-beta superfamily. Nature (1997) 4.34
Phosphatidylinositol 4,5-bisphosphate and Arf6-regulated membrane traffic. J Cell Biol (2001) 3.70
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood (2006) 3.59
Role of transforming growth factor Beta in human cancer. J Clin Oncol (2005) 3.53
Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell (1993) 3.51
Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem (1994) 3.49
Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J Biol Chem (1999) 3.17
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med (2012) 3.03
BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci (2007) 2.95
Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol (1995) 2.80
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther (2004) 2.55
How the Smads regulate transcription. Int J Biochem Cell Biol (2007) 2.46
Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res (2008) 2.43
Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem (2005) 2.03
A role for BMP heterodimers in roof plate-mediated repulsion of commissural axons. Neuron (2003) 1.75
Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9. Science (2000) 1.68
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene (2009) 1.58
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics (2009) 1.58
Bone morphogenetic protein-9. An autocrine/paracrine cytokine in the liver. J Biol Chem (2000) 1.48
Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem (2011) 1.48
BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J Cell Sci (2010) 1.43
Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation. Endocrinology (1995) 1.38
Differentially methylated regions of imprinted genes in prenatal, perinatal and postnatal human tissues. PLoS One (2012) 1.36
Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK. J Cell Physiol (2007) 1.31
Identification of receptors and signaling pathways for orphan bone morphogenetic protein/growth differentiation factor ligands based on genomic analyses. J Biol Chem (2005) 1.28
Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance. Mol Cell Biol (1987) 1.23
Characterization of a human ovarian teratocarcinoma-derived cell line. Int J Cancer (1980) 1.19
Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia (2011) 1.17
Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res (2009) 1.14
Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development. Proc Natl Acad Sci U S A (2013) 1.07
Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells. Oncogene (2014) 0.96
Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J (2013) 0.95
Circulating Bmp10 acts through endothelial Alk1 to mediate flow-dependent arterial quiescence. Development (2013) 0.94
BMP-9 induced endothelial cell tubule formation and inhibition of migration involves Smad1 driven endothelin-1 production. PLoS One (2012) 0.93
USP15 targets ALK3/BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling. Open Biol (2014) 0.93
BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231. J Cancer Res Clin Oncol (2011) 0.91
A homogeneous caspase-3 activity assay using HTRF technology. J Biomol Screen (2002) 0.90
Epigenetic determinants of ovarian clear cell carcinoma biology. Int J Cancer (2014) 0.89
Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett (2013) 0.89
BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways. PLoS One (2014) 0.87
The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas. Int J Cancer (2008) 0.86
Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3. Int J Oncol (2013) 0.84
BMP9 inhibits the bone metastasis of breast cancer cells by downregulating CCN2 (connective tissue growth factor, CTGF) expression. Mol Biol Rep (2014) 0.84
BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells. PLoS One (2013) 0.81